Inovio Pharmaceuticals 2025 Q1 Earnings Narrowed Losses Amid Positive Revenue Surprise

Inovio Pharmaceuticals (INO) reported its fiscal 2025 Q1 earnings on May 13th, 2025. Inovio exceeded expectations with a 31.08% earnings surprise, narrowing its net loss to $19.7 million, or $0.51 per share, better than anticipated. The company's promising revenue achievement of $0.07 million surpassed the Zacks Consensus Estimate by 30%, indicating strong demand for its offerings. Guidance remains in-line as Inovio is set to begin rolling submission for INO-3107 in mid-2025, aiming for FDA acceptance by year-end.

Revenue
Inovio Pharmaceuticals' revenue for the first quarter remained stable at $65,343, primarily driven by contributions from collaborative arrangements and other contracts. This marks a noteworthy shift from zero revenue recorded in the same quarter last year, highlighting the company's ability to generate income.

Earnings/Net Income
Inovio Pharmaceuticals narrowed losses to $0.51 per share in 2025 Q1 from $1.31 per share in 2024 Q1, indicating a substantial improvement. The net loss decreased by 35.4% to $19.69 million in 2025 Q1, showcasing positive momentum. This improvement in EPS demonstrates the company's effective cost management and strategic initiatives.

Price Action
The stock price of Inovio Pharmaceuticals has edged down 2.54% during the latest trading day, jumped 12.28% during the most recent full trading week, and surged 21.52% month-to-date.

Post-Earnings Price Action Review
Inovio Pharmaceuticals' strategic decision to hold shares for 30 days after revenue announcements has shown promising results. The company reported a 31.08% earnings surprise and a 30% increase in revenue, exceeding estimates for the first quarter of 2025. This reflects Inovio's focus on operational efficiency and strategic positioning in the biotechnology sector. The positive performance indicates potential for continued growth and profitability. The market has reacted favorably to Inovio's earnings report, with the stock experiencing notable gains. Investors should continue monitoring Inovio's progress in clinical trials and regulatory submissions, as upcoming developments may influence future stock performance.

CEO Commentary
Jacqui Shea, President and Chief Executive Officer, expressed optimism regarding Inovio Pharmaceuticals' progress towards submitting the BLA for INO-3107, their lead candidate for recurrent respiratory papillomatosis (RRP). She highlighted the resolution of manufacturing issues and the initiation of design verification testing as key achievements. Shea emphasized the importance of ongoing market research, which reinforces the belief that INO-3107 could become the preferred treatment for RRP if approved. She also noted promising interim results from their DNA-Encoded Monoclonal Antibodies technology, affirming the potential for future advancements in their DNA medicine pipeline.

Guidance
Inovio Pharmaceuticals anticipates submitting the BLA for INO-3107 through a rolling submission starting mid-2025, with completion expected in the second half of the year. The company aims for FDA acceptance of the complete BLA filing by year-end 2025, potentially leading to a PDUFA date in mid-2026 if priority review is granted. Financially, Inovio reported a net loss of $19.7 million for Q1 2025 and has a cash runway projected into Q1 2026, estimating a net cash burn of approximately $22 million for Q2 2025.

Additional News
Inovio Pharmaceuticals has made significant strides in advancing its regulatory milestones and product pipeline. The company has initiated device verification testing for its CELLECTRA delivery device, crucial for the Biologics License Application (BLA) submission for INO-3107. Additionally, the European Medicines Agency's Committee for Advanced Therapies certified the quality and non-clinical data for INO-3107, enhancing its potential for European market entry. Inovio has also announced the appointment of Steven Egge as Chief Commercial Officer, bringing extensive experience in HPV-related diseases and vaccines, which aligns with the company's strategic focus on DNA medicines.